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High throughput sequencing (HTS) generates large amounts of high quality sequence data for microbial genomics.
The value of HTS for microbial forensics is the speed at which evidence can be collected and the power to
characterize microbial-related evidence to solve biocrimes and bioterrorist events. As HTS technologies continue to
improve, they provide increasingly powerful sets of tools to support the entire field of microbial forensics. Accurate,
credible results allow analysis and interpretation, significantly influencing the course and/or focus of an investigation, and
can impact the response of the government to an attack having individual, political, economic or military consequences.
Interpretation of the results of microbial forensic analyses relies on understanding the performance and limitations of
HTS methods, including analytical processes, assays and data interpretation. The utility of HTS must be defined carefully
within established operating conditions and tolerances. Validation is essential in the development and implementation
of microbial forensics methods used for formulating investigative leads attribution. HTS strategies vary, requiring guiding
principles for HTS system validation. Three initial aspects of HTS, irrespective of chemistry, instrumentation or software
are: 1) sample preparation, 2) sequencing, and 3) data analysis. Criteria that should be considered for HTS validation for
microbial forensics are presented here. Validation should be defined in terms of specific application and the criteria
described here comprise a foundation for investigators to establish, validate and implement HTS as a tool in microbial
forensics, enhancing public safety and national security.
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BioinformaticsBackground
Microbial forensics involves analysis of microbe-related
materials found at a crime scene, suspected laboratory,
and so on, for forensic attribution and, thus, can be pivotal
for developing investigative leads. Attribution (assigning
to a source) can be defined as the characterization of a
sample with the greatest specificity, which in the case of a
microorganism would be at the species or strain level and
ideally at the level of the isolate or even the culture vessel
(for example, flask) from which the sample originated.* Correspondence: bruce.budowle@unthsc.edu
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unless otherwise stated.High throughput sequencing (HTS) vastly improves the
possibility that the forensic and scientific communities will
be able to assign features to bio-forensic evidence, such as
specific identity for unknown or emerging pathogens,
sample or microbe origin, antibiotic sensitivity, evidence
of genetic engineering and virulence profile. Now that
a number of laboratories can afford HTS systems,
community-accepted validation guidelines or standards
are needed. As with any analytical tool(s) for forensic
application, the utility of HTS operating conditions and
tolerances and interpretation guidelines must be carefully
defined. Guiding principles must be established to validate
HTS systems. Here we define the criteria and offer a
process for validation of HTS systems in microbial
forensics. If methods are validated within the framework
outlined here, microbial forensics will achieve an everal Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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Budowle et al. Investigative Genetics 2014, 5:9 Page 2 of 18
http://www.investigativegenetics.com/content/5/1/9higher level of power and analytical value and, ultimately,
greater protection for the public and the nation’s safety
and security.
Introduction
More than a decade ago the United States experienced a
simple but effective biological attack in which Bacillus
anthracis endospores were placed in envelopes and
delivered by the US postal service to intended victims
[1-4]. The Federal Bureau of Investigation initiated the
Hazardous Material Response Unit in 1996 to undertake a
forensic investigation of bioterrorism events. Despite this
effort, in 2001 the forensic infrastructure was inadequately
prepared to analyze and interpret the available microbio-
logical evidence to assist in determining who did and did
not have the capacity to perpetrate such an attack. In fact,
much of the needed forensic science applications had not
yet been developed or validated. As part of an immediate
national response to investigate such crimes, the field of
microbial forensics was born [5-7] and its emergence was
accelerated by the urgent requirement to investigate the
anthrax mailing attacks.
The foundations of the field of microbial forensics lie
in public health epidemiology and its practices [6-10] as
well as agriculture practices [11-13]. Microbial forensics
involves analysis of microbe-related materials found at a
crime scene, suspected laboratory, and so on for forensic
attribution (assigning to a source) and, thus, can be
pivotal for developing investigative leads. Attribution in
the case of microbial forensics can be further defined as
the characterization of microorganisms within a sample to
the species or strain level and ideally to the specific isolate
or culture vessel from which the sample originated. Indeed,
metagenomic approaches to assess microbial composition
of samples also may provide strong microbial forensics
evidence (either phylogenetically by identifying a specific
target organism in the complex sample or by abundance
spectrum profile) to attribute sample(s) to source. Scientific
attribution also eliminates as many other candidate isolates
or sources as possible and supports both investigation and
legal proceedings.
The standards and requirements for microbial forensic
practices are less well defined than those within human
identification and other established forensic disciplines.
However, establishing the validity of microbial forensic
methods and their use and interpretation contributes to
acceptance, admissibility, confidence, value and weight
of physical evidence in the jurisprudence process [14] as
well as within the military, intelligence and homeland
security sectors that have the responsibility to act upon
data and reports associated with suspected bioterror
activities. Within two years following the anthrax
letter attacks, the FBI’s Scientific Working Group for
Microbial Genetics and Forensics (SWGMGF) formalizedand published Quality Assurance (QA) guidelines [7]. The
motivation for establishing a QA system was to put quality
practices in place to ensure that microbial forensic
evidence was analyzed using the best practices possible
and that the interpretation of results was based on extant
data and sound principles.
The SWGMGF QA guidelines were a good first step
in establishing a QA system for microbial forensics and
for increasing confidence in the data generated. However,
as technologies advance and application of microbial
forensics expands beyond the traditional law enforcement
communities, it becomes increasingly important to
continue to build upon the SWGMGF guidance and
previously published microbial validation methods [7] to
reflect the current state-of-the practice and foster greater
community wide acceptance. Significant drivers to expand
validation guidance include the substantial developments
and applications of next-generation or HTS. For perspective,
the first bacterial genomes that were sequenced in 1995 by
the Institute of Genome Research (Rockville, MD, USA)
[15,16] took more than three months to complete. Although
HTS technology was initially developed, in part, for charac-
terizing human genomes [17-19], these instruments have
increasingly been used successfully to characterize unknown
microbes in samples of varying complexity [20-42]. Within
the field of microbial forensics [7,43,44], HTS combined
with powerful bioinformatics capabilities offers a powerful
tool to characterize forensic bio-evidence, including
unknown microorganisms, genetically-engineered micro-
organisms and low-abundance (or trace) microorganisms
present in complex mixed samples with extremely high
sensitivity [45]. HTS technologies have features that make
them more desirable and accessible for microbial forensic
analyses than Sanger sequencing [46], including high
throughput, reduced cost (on a per nucleotide or per
genome basis) [47] and large-scale automation capability.
Millions of sequencing reactions can be performed in a
massively parallel fashion in a single instrument run
[48-53]. With many copies sequenced at any desired
portion of the genome (known as coverage), consensus
sequence accuracy can be increased far beyond the
per-read accuracy rate. As the throughput and accuracy of
HTS continues to increase, more samples can be multi-
plexed in a single run without sacrificing depth of coverage
or more complex samples may be analyzed at a greater
depth of coverage.
Several HTS platforms are available and currently used
for microbial sequencing, usually based on massively
parallel sequence by synthesis strategies with high accuracy
in a reduced footprint compared with Sanger sequencing.
The primary HTS platforms include the HiSeq and MiSeq
from Illumina (San Diego, CA, USA), the Ion PGM and
Ion Proton Sequencers from ThermoFisher (South San
Francisco, CA, USA) and the 454 systems from Roche
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is the latest platform on the market in this desktop category
with 150 Gigabase throughput and ‘push-button simplicity’.
Another type of sequencing chemistry, developed by
Pacific Biosciences (PacBio, Menlo Park, CA, USA), is
the first to utilize single molecule real time (SMRT)
sequencing, in which each base is detected in real time as
a polymerase adds fluorescently tagged nucleotides along
single DNA template molecules. SMRT sequencing is
distinct from the other HTS technologies in providing
very long read lengths. The average read length with the
PacBio RS instrument is approximately 3,000 bp and can
reach up to 20,000 bp [54]. Furthermore, examining the
polymerase kinetics of SMRT sequencing allows for direct
detection of methylated DNA bases [55]. This intrinsic
capability of the SMRT sequencing workflow does not
affect primary sequence determination, while yielding
yet another forensic signature that is not captured
with standard protocols on other HTS instruments.
A new and potentially revolutionary sequencing
platform in development by Oxford Nanopore (Oxford,
United Kingdom) will allow a single DNA molecule to pass
through a protein nanopore set within an electrically resist-
ant membrane bilayer. The resulting cross-membrane
current fluctuations are used to identify the targeted nu-
cleotide [56]. The company projects sequencing rates ini-
tially will be 20 bases per second, increasing to 1,000 bases
per second in the future, and providing read lengths up to
tens of thousands of bases [57]. While these individual
reads will contain a larger number of errors than the other
mentioned HTS instruments, the PacBio (and potentially
the Oxford Nanopore) errors are random. With redundant
interrogation of the same base of a circular template with
SMRT sequencing and with sufficient depth of coverage,
highly accurate consensus calls can be obtained [54].
HTS vastly improves the possibility that the forensic
and scientific communities will be able to assign features
(for example, strain identity, virulence profile, and so
on) and, ultimately, attribution to bio-forensic evidence.
However, these improvements cannot be realized or
known with any level of statistical confidence without
effective and validated bioinformatics tools to process,
analyze and interpret the large amounts of HTS data
generated. Most application-oriented laboratories are
unlikely to have in-house bioinformaticians, and even
for laboratories with such resources, a comprehensive
data analysis pipeline must be defined and validated to
establish that the software algorithm(s) reliably analyze
sequence data and produce accurate final results. Many
bioinformatic tools are available within commercial,
academic and other open sources. However, the specific
tools employed or developed are highly dependent on
the need and intended use of that laboratory and may
not have been rigorously tested. An appropriate dataanalysis pipeline must be implemented and fully validated,
including understanding the uncertainty and error associ-
ated with each step of the process, as well as the collective
uncertainty. The appropriate interpretation and weight
of the evidence must be employed successfully and
effectively communicated.
Now that laboratories are implementing HTS systems,
community-accepted validation guidelines or standards are
needed. Development of HTS technologies and associated
bioinformatics tools will continue to progress rapidly, and,
no doubt, increasingly powerful tools will be available to
support microbial forensics. HTS applications for microbial
forensics include assembly of draft and finished single
genomes of microorganisms, targeted site sequencing,
metagenomics (both amplicon sequencing of conserved
genes for microbial community structure and shotgun
sequencing for profiling the content of a sample), and
source attribution, including profiling, sample comparison,
sample engineering, and other microbial evolution or
epidemiology applications. As with any analytical tool(s)
for forensic application, the utility of HTS operating condi-
tions and tolerances must be carefully defined. Regardless
of the variation in technologies and software, guiding
principles, such as the criteria listed in Table 1, must be
established to validate HTS systems. Here we define the
criteria and offer a process for validation of HTS systems
in microbial forensics. Rather than delineating a set
of protocols for a particular set of tools and reagents
that apply to a limited set of instances, which may quickly
become obsolete, those tools and reagents universally
needed for protocol validation are described. By addressing
each area described below, an investigator will be able to
establish, validate and implement HTS as a tool for
microbial forensics.
Application and validation of HTS for microbial
forensics
Microbial forensic applications of HTS include single
isolate sequencing with de novo assembly, read mapping,
targeted sequencing of specified genes or other regions
of interest (which generally include diagnostic markers,
for example, SNPs, indels, and so on) [63,64], and meta-
genomics. Metagenomics analyzes by sequencing DNA
(or RNA) samples to identify or describe microbial com-
munity composition of environmental samples such as
soil [65], plants [41,42], sea water [66,67], hospital
environments [68] and human-associated habitats [69,70].
HTS makes metagenomics readily feasible since
culturing is not required for sample enrichment. HTS
and associated bioinformatic technologies make it
possible to detect microorganisms of interest when
they are present in low abundance and differentiate
them from near neighbors by using diagnostic genomic
signatures.
Table 1 Validation criteria for analytical performance metrics
Criteria Definitions
Analytical sensitivity Likelihood that the assay will detect a target (for example, organism variant, sequence region,
functional element, and so on) in a sample (that is, target), if present; can include target attribution
when defined as strain- or isolate-level detection. Also known as the true positive rate. Calculated
by dividing number of true positives by the sum of true positive and false negatives (TP/(TP + FN)).
Analytical specificity Likelihood that the assay will not detect a target, if not in the sample; can include false target attribution.
Also known as the true negative rate. Calculated by dividing true negatives by the sum of true negatives
plus false positives (TN/(TN + FP)). May be impractical to calculate for methods designed to detect the
known universe of organisms.
Precision The degree that individual measurements of the same sample are similar with regard to the presence
and absence of target. Determined by the distribution of random errors and not the true or underlying value.
Accuracy Degree that the material measured is similar to its true value. Calculated by (TP + TN)/(TP + FP + FN + TN).
Reproducibility The degree to which the same result(s) is obtained for a sample when the assay is repeated between/among
different operators and/or detection instruments.
Repeatability The degree to which the same result(s) is obtained for a sample when the assay is repeated by the same
operator and/or detection instrument.
Limit of detection Minimum level of input material for a target as a proportion of the total at which all replicates are consistently
positive for that target.
Reportable range The region(s) of genome(s) that are sequenced and from which information is drawn for comparison or attribution.
False positive rate The rate at which a target is incorrectly called as present. Also known as Type I error. Calculated as 1 – specificity
False negative rate The rate at which a target organism is incorrectly called as absent. Also known as Type II error. Calculated
as 1 – sensitivity.
Assay robustness Stability of analytical performance under variable conditions, that is, likelihood of assay success.
Reference materialsa Materials/samples used to test the performance of the assay (for example, reference panels of the target
and mock or non-probative materials) relevant to the intended application of the assay.
Databasesa Collection of data and reference genomes, genes and genomic elements to be used for interpretation of results.
Interpretation criteria for resultsa Analysis (quantitative or qualitative) used and confidence level of a result (match, association, most recent
common ancestor, and so on).
aThese last three items – Reference materials, Databases, and Interpretation criteria – typically have not been considered validation criteria. However, they have
been included here primarily because interpretation of results is an essential part of generating reliable and appropriate results, which should be described within
a standard operating protocol (SOP). The data used to test a system are reliant on reference materials and, depending on the situation, databases. See [58-62].
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public expect forensic methods to be validated, when
feasible, prior to use on forensic evidence. A validation
process is essential in the development of methods for
microbial forensics, and such methods must be reliable,
defensible and fit for purpose.
Validation has been described as the process that:
1. Assesses the ability of procedures to obtain reliable
results under defined conditions.
2. Rigorously defines the conditions that are required
to obtain the results
3. Determines the limitations of the procedures.
4. Identifies aspects of the analysis that must be
monitored and controlled.
5. Forms the basis for the development of
interpretation guidelines to convey the significance
of the findings [58].
While these general principles apply to HTS technologies
and guidelines specifically for HTS used in metagenomic
profiling already exist [71], there are challenges that arisewhen validating HTS for microbial forensics that require
further consideration. Here we describe the specific
guidelines for validating HTS technologies so that the
microbial forensics community (and others) will have a
common protocol and lexicon to leverage the exciting
potential of HTS while maintaining high quality and confi-
dence under rigorous scrutiny when this technology is used
to support investigations of bioterrorism or biocrimes.
General considerations for validation
The requirements for validation will vary according to
the process in question and should be defined in terms
of the specific application. While full developmental and
internal validation is ideal [7,58], this requirement
may not be practical for all situations, such as an attack
involving a novel agent not in previously validated
systems. Indeed, the use of multilocus variable number of
tandem repeat (VNTR) analysis [72] to determine that the
strain of B. anthracis in the 2001 letter attack was Ames
was not a fully validated procedure in casework analysis.
Yet, it was sufficiently developed for investigative lead
value [73].
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biological diversity of microbes and the potential of
having to deal with a large number of samples in a
microbial forensic case, it is not possible to validate
every scenario. Moreover, HTS and bioinformatics
technologies are changing rapidly and will continue
to be improved in the immediate and long-range future.
Lastly, exigent circumstances may require immediate
response, and microbial forensics should be able to lend
support using all available tools. For such unforeseen
circumstances preliminary validation may be ‘carried out
to acquire limited test data to enable the evaluation of a
method for its investigative-lead value, with the intent of
identifying key parameters and operating conditions and
of establishing a degree of confidence in the methods of
collection, extraction, and analysis’ [74]. However, once
general validation is accomplished for instrumentation,
bioinformatics data analysis, and Standard Operating
Protocols (SOPs), only novel aspects of validation for new
targets may be needed to generate informative leads and
to make public health decisions with associated levels
of confidence. Therefore, it is extremely important to
establish comprehensive criteria for validation of HTS
technologies with all aspects of the validation study
documented. The fact that a validation study is preliminary
should be stated clearly, with the limitations of the assay
and validation study clearly described. However, validation
of finalized SOPs is essential for reliable and defensible
use of HTS technologies in microbial forensics. Sample
collection and storage have been addressed elsewhere [75]
and will not be described here. Validation of the HTS
process addressed here relies, in part, on reports available
in the literature [59-61,76] that have defined validation
requirements for HTS applied to human clinical genetic
analyses. The validation guidelines for the three major
technical components of HTS (sample preparation,
sequencing and data interpretation) as related to the field
of microbial forensics, are presented in the following
sections.
Sample preparation
Nucleic acid extraction – quantity and purity
Validation should include anticipated sample types and
matrices of those sample types. A range of routinely
anticipated types of samples incorporating an array of
quality and quantity of nucleic acids, environmental
matrices, inhibitors of downstream analytical processes
and biological contaminants expected to impact reliability,
specificity and obtaining results, should be included.
Template DNA (or RNA, even though DNA is referenced
here) must be of sufficient quantity and quality for library
preparation and sequencing. The amount of DNA available
will influence the library preparation method used. At the
time of preparation of this manuscript, for example, theTruSeq (Illumina, Inc.) sequencing preparation method
requires approximately 100 ng to 1 μg [77], Haloplex
(Agilent, Santa Clara, CA, USA) 225 ng [78], Nextera
XT (Illumina) 1 ng [79], and polymerase chain reaction
(PCR)-based methods, though variable, may require less
than 1 ng. Minimum and maximum DNA requirements
for analysis should be established using a laboratory’s
work flow. A set of guidelines is needed to establish what
levels of prepared DNA may be insufficient or compromised
and how to proceed under such circumstances (for example,
analyze anyway, stop, or select an alternate assay).
Metrics based on precise quantitative pre-analytical
sample characterization are needed to assess the fraction
of template molecules that meet the requirements for
downstream analyses, which is important for amplicon
sequencing and shotgun sequencing. It is likely that
samples from which the DNA is insufficient, damaged
and/or inaccessible will be encountered, especially when
collected from the environment. This information will be
helpful to assess and compare potential downstream
partial and/or complete loss of target data. The DNA
extraction method used should be tested for yield and
sufficient purity for downstream analytical processes.
Additional extraction processes may include separating
a particular genome from a metagenomic sample or
selective filtration to separate specific types of microbes,
such as virus particles in a metagenomic sample [71,80] or
methylated DNA from non-methylated DNA [81]. Since
host DNA or background genome(s) may comprise a
major component(s) of a given metagenomic sample, the
ability to sequence minor components of complex
samples may be affected. Purification procedures used
to maximize the yield of targets of interest should be
evaluated the same as the nucleic acid purification
process. Lastly, proper positive and negative controls
should be included to assess process performance and
laboratory background contamination, respectively.
Enrichment and library preparation
DNA samples, single source or metagenomic, may be
enriched for specific target regions of genomes using
a capture approach or PCR. For many enrichment
processes the desired genomic regions should be
known and defined in order to design the protocol.
However, whole genome amplification methods such
as non-specific or degenerate PCR primers, [82,83]
including multiple displacement amplification [84], can be
used. The methods used for genome amplification can
impact the results by introducing contaminating chimera
formation and sequence bias [71], and should be consid-
ered, depending on the method or assay during validation.
Capture- and PCR-based methods have both advantages
and limitations. PCR-based methods provide greater sensi-
tivity of detection, but are likely to produce greater error
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generated with a capture approach. PCR-based methods,
in which a multiplex panel of markers may be considered,
will require development of primer sets that amplify the
targeted sites in a balanced fashion (or at least describe
any significant imbalance) and do not cross-hybridize to
unspecified targets. In contrast, capture methods will
require more template DNA and would not provide the
limit of detection necessary for microbial forensic analyses
of trace materials. Regardless of the methods listed here or
new ones subsequently introduced, it is incumbent upon
the analyst to define validation criteria that address the
advantages and limitations of enrichment.
Whether or not a sample is enriched, the next step
in sample preparation is library preparation where the
DNA sample is modified for sequencing. DNA is typically
fragmented into shorter pieces by mechanical shearing
(for example, sonication) or enzymatic fragmentation
(for example, tagmentation [79,85]). Adapters are added
to each fragment of DNA to facilitate clonal amplification
prior to sequencing of the cloned fragments. Adapters can
be incorporated into existing amplicon fragments during
PCR. With long PCR amplicons, fragmentation may be
required. DNA fragments and/or PCR amplicons then are
size-selected for the range appropriate for down-stream
sequencing and quality assessment. This process generates
a library of millions of cloned fragments that are
ready for sequencing. Quality must be assured by testing
reproducibility of library preparations and robustness of
indexing (described below) to identify (or misidentify)
labeled fragments. Internal controls to monitor enrichment
and library quality should be considered.
Multiplexing
Multiplexing with HTS can be achieved by barcoding
(or indexing) [86,87]. Short unique sequence tags are
added to every fragment of a sample during library prepar-
ation to ‘tag’ the fragments unique to a sample. Thereby,
samples can be pooled (or multiplexed) and data separated
(that is, demultiplexed) after sequencing, based on the
unique tagged sequences. With the high throughput
capacity afforded by HTS, many different samples
may be sequenced simultaneously. For example, the
MiSeq and Reagent Kit V2 (Illumina) is capable of
generating more than 7.5 to 8.5 Gbp using a 2 × 250
paired-end run (about 39 hours sequencing run time).
With 8 Gbp of sequence data, 16 samples can be multi-
plexed on a single run assuming desired 100× coverage of a
5 Mb bacterial genome (5e6 bp genome × 100× coverage ×
16 samples = 8e9 bp MiSeq output). This calculation is just
an example and will change as throughput and read lengths
increase, which is likely to occur relatively quickly and
often. As the throughput of HTS continues to increase,
more samples could be multiplexed in a single run withoutsacrificing depth of coverage or more complex samples
may be analyzed at a greater depth of coverage. In theory,
hundreds to thousands of barcodes could be synthesized,
but currently 12 to 384 different reference samples can be
pooled in a single reaction [86,87]). The Earth Microbiome
Project provides >2,000 barcodes that could be combined,
theoretically enabling multiplexing of >4 million samples in
a single sequencing run [88]. Depending on the target, for
example, single source samples, the number of samples that
can be barcoded and sequenced in a single run should be
predictable. The performance of barcoding to identify
specifically tagged samples should be evaluated and
documented. Furthermore, when feasible, use of different
indexes in sequential sequencing runs on an instrument
can indicate if carry-over contamination has occurred,
which offers another quality control for monitoring poten-
tial impact of contamination on sequencing results.
Sequencing
Each HTS system employs a unique chemistry for
sequence determination and each will have to be validated
in general and then specifically according to applicable
features of the system [51,52,89-93]. For example,
chemistries employed by 454 and Ion Torrent systems
tend to be less accurate than Illumina-based chemistry for
sequencing homopolymers. The type of sequencing, either
single-end (fragments sequenced at one end only) or
paired-end (both ends are sequenced) can impact coverage
and stringency in different ways. Sanger sequencing, still
considered the gold standard, allows for some concordance
testing (that is, comparative analysis of the same target
sequence with different analytical systems). However, there
is no guarantee that the gold standard always provides the
correct result. For example, Harismendy et al. [94]
sequenced 266 kb of portions of six ion channel-related
genes using Sanger sequencing, three HTS platforms, and
one microarray platform and compared the results. The
portion of false negative (FN) and false positive (FP) single
nucleotide polymorphisms (SNPs) attributed to Sanger
sequencing were 0.9% and 3.1%, respectively. Moreover,
the lower throughput and coverage of Sanger sequencing
makes it impractical for concordance testing with HTS
generated data. The data generated by HTS are so much
greater per run than those generated by Sanger sequencing
that only limited sampling and very short regions can
be reasonably compared. Instead concordance testing
may be better achieved by testing orthogonal HTS
systems with templates of ‘known’ genome sequence.
Potential errors and biases inherent in each HTS system
may be determined and documented better in this
manner. For each sample type and platform, the error
rate (and error profile) of sequencing can be determined
only by empirical testing. The data can be used to define
limitations of the current system that should be part of an
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allows for identifying weaknesses and enables assay
improvements before implementation. Where possible,
orthogonal analyses should be employed for validating
HTS methods.
Data analysis and interpretation
The final major components of HTS validation are data
analysis and interpretation of results. Bioinformatics is
essential and critical because of the massive amount of
data, the requirement to answer forensic and investigative
questions using the data, and the questions that may be
addressed with trace samples, complex samples, potential
genetic engineering, and background endemicity (that is,
microorganisms that generally are found at a location).
Comprehensive data analysis pipeline(s) should be defined
and validated. It is important to establish that the software
algorithms reliably analyze sequence data to produce
accurate final results. The flow of data generally progresses
through base calling, quality control and, finally, down-
stream taxonomic, functional and/or comparative analysis
(which is generally either alignment- or fragment-based, if
assembly is not performed) (Figure 1).
Quality metrics, generated during the analytical process,
include: quality scores for base calling, read-level quality
control (QC) (to include trimming of low quality bases
on fragment ends), alignment, GC content, depth of
coverage, strand bias and variant calling. Base calling,
the identification of the specific nucleotide present at
each position in a single read, should be part of
instrument software. A quality threshold of base scoring is
typically set with a Q score. A threshold of Q20 sets
the minimum base call accuracy at 99% allowing for
an incorrect base call per read at 1 in 100, while a
Q30 score sets the accuracy at 99.9% and incorrect base
call per read at 1 in 1,000 [95]. A Q score threshold
should be set for both validation studies and subsequent
implementation. However, there are no guidelines that
suggest that, for example, a Q20 score is a requirement.
A less than Q20 score may not impact accuracy as subse-
quent coverage and annotation may be adequate. Under
defined conditions and for investigative leads or exigent
circumstances the quality score may be relaxed; however,
the justification or reliability of a lower score must beFigure 1 Basic schematic of data flow through an analysis process. Th
software, and each downstream step must be included in the validated an
reads is required, for example with contig building and/or alignment, anddocumented. Each HTS platform will have specific
sequencing limitations and errors: signal-intensity decay
over the read, erroneous insertions and deletions, strand
bias, and so on. These limitations should be described
and defined.
Accuracy of identifying sequence variants (for example,
SNPs, indels, chromosomal rearrangements, copy number
variants) is dependent on a number of factors that include
base calling and alignment as well as choice of reference
genome, depth of sequence coverage (as well as average
coverage), and sequence chemistry/platform. Because align-
ment involves arranging a read with a reference sequence
(targeted or whole genome), different alignment strategies
can and do produce different results (Figure 2). Differences
in alignment will vary with software, so rules for alignment
should be defined for consistency and traceability.
Choice of a reference genome, if used for alignment is
important. Because the reference will vary by species and
circumstance, specific criteria for selection are not provided
here. However, it is incumbent upon the analyst to develop
criteria for the reference genome that is selected. For
example, from a microbiological perspective, a reference
may be one that is accessible, is relevant as the Type
strain, is relevant from a public health perspective, or is
well-defined microbiologically; and from a computational
perspective, it may be one, several or a collection of
genomes, or the optimal computational sequence, and
should be curated, such as a finished genome. Validation
should define the purpose of the reference genome and
describe the criteria for selection.
Minimum criteria should be established by the laboratory
for the output of the selected analytical method, such
as depth and uniformity of coverage. Defining output
thresholds for metagenomic samples may be difficult
given the immense quantity of data and microbial
diversity; therefore, single source samples and defined
mixtures can be used as a guide. These limitations
may be necessary in defining FNs and FPs. Clearly, there
will be ambiguous calls due to sequencing noise and novel
genome composition. The specific parameters and settings
used to establish thresholds, FP and FN rates should
be detailed thoroughly to enable sound interpretation
and accurate comparison to alternative methods and
protocols.e first step of base calling generally is completed by the instrument
alytical pipeline. Additional data processing after generating sequence
will depend on the application.
Figure 2 Alternate alignments of identical sequences. Reads 1 and 2 are aligned in equally optimal ways that indicate different locations for
a 2 bp deletion relative to the reference. Differences in alignment can be problematic when an evidence sample’s consensus alignment is based
on a different approach than that of the reference sample or entries in a database.
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respect to the accuracy of variant calling. The limitations
should be described and quantified, and algorithms may
need to be modified to address specific limitations. The
method(s) of identification and annotation should be
described. Different formats are available for exporting
variants and annotations [59]. The file format should
include ‘a definition of the file structure and the
organization of the data, specification of the coordinate
system being used, e.g., the reference genome to which the
coordinates correspond, whether numbering is 0-based or
1-based, and the method of numbering coordinates for
different classes of variants, and the ability to interconvert
to other variant formats and software’ [59].
The FP and FN rate often are determined for most
analytical assays. However, there are additional consider-
ations with HTS and microbial identification. Similar to
homologous regions and pseudogenes for human genetic
variation testing [60], the homologous regions of a near
neighbor (for example, genes shared across the bacterial
kingdom) become important for target identification
(target being the species or strain of interest). Generating
a metagenomic profile at the resolution of the phylum
level, or even the genus level, may indicate a general
environment from which a sample originates but
often cannot identify the microorganism of interest at
the species or strain level. However, newer approaches
have started to achieve strain level identification
[96-99] by exploiting higher throughput and novel
algorithms. The results can be accurate and reliable
and can translate into identification of the target
agent in an unknown complex sample. Many reliable
reads of the sequence of any particular species will
share the same sequence, particularly so with near
neighbors. For example, while Bacillus species may be
sufficiently diverse to discriminate in a particular assay,
strains of B. anthracis are nearly indistinguishable from
one another [100]. FPs must be defined by specificity
and the ability to phylogenetically differentiate a species
(or strain) from near neighbors, such as Bacillus anthracis
and Bacillus cereus. Testing that a known single source
sample fits in a phylogenetic schema is not the same as
identifying a particular species in a simple or complex
sample. Methods for identification of targets should be
validated based on intended use. FN rate may be difficultto determine for metagenomic sample analyses as
stochastic effects and sampling variance may impact
detection of the target(s). Known data sets can be
helpful to define the FN rate.
Once assay conditions and pipeline configurations
have been established, the entire method should be
tested prior to use. Although individual components
may have been validated, it is imperative to demonstrate
that valid and reliable results are obtained when the com-
ponents are combined. The standard microbial forensics
validation criteria [7,58] apply to HTS methods as well.
Special attention should be given to accuracy, precision,
analytical sensitivity and specificity, reproducibility, limits
of detection, robustness, reportable range, reference range,
either FN/FP or confidence, statements of findings and
databases used (Table 1). The laboratory must select and
be able to clearly and defensibly state the parameters and
thresholds necessary to determine whether the overall
sequencing run is of sufficient quality to be considered
successful. Criteria should include error rate, percentage
of target captured, percentage of reads aligned, average
and range of coverage depth, and so on.
Reference materials
Reference materials (RMs) should be used during test
validation. Well-characterized reference samples should
be included to establish baseline data to which future
test modifications also can be compared [60]. Many
different types of samples can serve as RMs for HTS,
including characterized DNA derived from specimens
prepared from microbial cultures, samples collected
from several different endemic regions with high
incidence of microorganisms of interest, samples from
several non-endemic regions discovered accidentally and
described as isolated outbreaks or findings, synthetic
DNA (sets of sequences of known isolates), or electronic
data (that is, generated in silico). A gold-standard reference
genome would contain a single gap-less sequence for each
chromosome or plasmid in the source organism, with no
ambiguous bases. RMs are homogeneous for single source
samples, stable and defined. Because complex mixtures are
likely to be unstable and subject to stochastic effects,
simple mixtures should be used. In silico complex
samples, which can be considered stable, are suitable
for testing the bioinformatics pipeline. The sequences
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documented. The same rationale can be applied to
positive controls, which must be defined. Negative
controls may include no-template controls, blank controls
for different phases of the analytical process or DNA
samples void of the target.
Bioinformatics software management
The bioinformatics community has not yet defined
uniform guidelines or protocols for benchmarking
software. Thus, users must fully validate and document
their bioinformatics pipeline. Software may be open source,
purchased from commercial entities, developed in-house,
or come from a combination of sources. The software
programs should perform general quality metrics
assessment, but the software likely will differ in
performance and potentially yield different results.
Therefore, accurate versioning of the state of the software
is essential [76], not just for validation but also for data
analyses. The software and modifications must be
tracked. Settings that can be modified by the user
should be documented. Documentation also should
include the specific version(s) of each component of
the pipeline, the hardware, dates of use and changes
to software. Each software upgrade requires revalidation
of the steps downstream of HTS. Virtual Machines [101],
which are software simulation(s) of a machine, encompass
the entire computational environment used for analysis
and can help accomplish comprehensive version control
on this complete system. By maintaining informative
curated reference datasets, validation of updates or
changes to software pipelines may be facilitated without
any additional HTS or with only minimal effort.
Analysis by computer software is an essential component
of using HTS data. Two general criteria addressing
software performance are verification and validation.
According to the Institute of Electrical and Electronics
Engineers (IEEE) Std 610.12-1990 [102], verification is ‘the
process of evaluating a system or component to determine
whether the products of a given development phase satisfy
the conditions imposed at the start of that phase,’ and
validation is ‘the process of evaluating a system or compo-
nent during or at the end of the development process to
determine whether it satisfies specified requirements.’
Since verification applies to whether the software system
was built correctly and validation is whether the intended
use was met, most users will only have tools at their
disposal to perform a validation of software. To be
considered validated, software must be tested using
input data that replicate challenging real-world situations.
Software can be integrated within the HTS process
(for example, instrumentation) for data generation
and external to the HTS system for interpretation
(for example, phylogenetics, attribution, and so on).The software specifications should conform to the
intended use [103]. Performance characteristics must
define the entire process addressed by the software
and individual process steps, as appropriate. Much of
the above discussion on data generation addressed the
criteria that relate to performance of data generation
and subsequent interpretation and, thus, serves as a
guide for software performance characteristics. Users
who create software for intended applications should
refer to the standards by the IEEE [102]. However, the
majority of users in the application-oriented laboratory
will obtain commercially-available software, and so
validation likely will be at the ‘black box’ level. Even
without access to the source code, users still are
responsible for ensuring that the software performs
the intended functions correctly. Regardless, since
software requirements often are derived from overall
system requirements for the HTS analytical tool, a
systems approach is recommended for validation. The
user’s intended use and needs [103] drive the criteria
for validation. When possible, the user can rely on
the manufacturer’s data for some of the validation, if
the data are made available, or on the scientific literature.
Nevertheless an internal validation demonstrating that
performance criteria are met is required. Software is
different than instrumentation in that it does not wear out
[103], and likely will be modified for better performance
over the lifespan of its use (however, the computer operat-
ing system can change, rendering the software incompatible
with the newer system). Since software will be modified
and updated, a validation analysis should be conducted for
the specific change(s) following the same principles of
validation. New problems may arise with the intended
update and, therefore, any impact that modification
may have on software beyond the change should be
tested using a systems approach [103].
Data storage
Permanent storage of all raw HTS data is not practical
as the raw data are exceedingly large. After base-calling,
this information is routinely discarded. Sequence data
should be in conventional, widely used format(s), for
example, .fastq files for sequence reads, or be readily
convertible to a standard format [59]. Many bioinformatics
pipelines create output data structures that may be
compressed and stored as an alternative to the .fastq read
files. Other compression systems have been proposed for
HTS data [104,105], but there may be utility in widely
used methods like gzip compression that will likely remain
in use for years to come. A best practice should be to
create a process so that results can be re-analyzed as
necessary when updates are made to the downstream
bioinformatics systems. Other files to archive include:
SAM/BAM (mapping data) and vcf (variants). These or
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about known SNPs of special diagnostic power, such as
canonical SNPs. Where possible, DNA samples should be
stored for re-testing [76]. Because of limitations with large
amounts of data, it is necessary that reference datasets
are documented and maintained in order to perform
validation of future software updates. Lastly, conversion of
data from one format to another could create unforeseen
transcription errors; therefore, defined data sets should be
tested before and after data conversion for accuracy.
Interpretation and reporting
Interpretation of results for attribution should be
defined clearly and documented. Equally important, the
level of resolution possible with a particular system should
be stated. Also, the database(s) used for validation
(and for casework analysis) is likely to be expanded
and improved with HTS technologies on a relatively
rapid basis; so the records of the database(s) used for
individual analyses must be maintained. The target
areas that define a species or strain and resolve it from
near neighbors are critical [100,106]. One or more sites
may be required depending on phylogenetic resolution. A
minimum number of targets and degree of confidence
with the number of targets should be established [107].
The means by which a software pipeline determines
attribution may not be accessible to the user, in which case
all relevant output data and associated thresholds should
be documented and stored in a standard way according to
the SOP. The minimum number of reads is essential for
limits of detection, stochastic effects, and FNs and FPs
and should be defined empirically for obtaining a reliable
result(s). An interpretation statement(s) and degree of
confidence (qualitative or quantitative) should be
developed regarding attribution of the sample, and that
confidence, when feasible, should be based in a rigorous
statistical framework.
Resequencing assembly can be effective if the reference
dataset contains sequences of closely related reference
genomes [71]. De novo sequencing is computationally more
demanding. Thus, the software and, just as importantly,
reference data sets are critical to result quality. There are a
number of assembly algorithms that can take millions of
short reads generated by HTS and translate them into a
portion or complete genome sequence [108-112]. Each
approach has benefits and limitations affecting quality and
efficiency. Therefore, specific software used, standard
metrics (for example, N50, coverage, contig sizes) assump-
tions and criteria applied should be documented [113,114].
While there may be some situations in which assembly
is required, it is less likely to be used or even necessary
for the foreseeable future in microbial forensics analyses
and especially with mixtures or metagenomic samples
where near neighbors, strains and coverage constraintsreduce the practicality of assembly. Alignment strategies
or fragment counting strategies are preferable to
assembly. Sequence alignment compares DNA sequences
(although it can apply to any kind of sequence data)
and seeks to identify regions of homology. More often
a reference sequence will be maintained, targeted
short reads will be aligned with that reference, and
differences with respect to the reference will be listed
(as ‘variants’) [115-117]. In addition to the same
documentation requirements for assembly strategies,
the reference sequence should be fully documented. While
we believe that alignment strategies will be favored over
assembly strategies for metagenomic microbial forensic
applications, if capabilities improve that enable effective
assembly, then it is incumbent upon the user to validate
the process.
Taxonomic assignment
Methods for read-based taxonomic classification of metage-
nomics data fall into two broad categories: composition-
based and alignment-based. Composition-based approaches
rely on comparing signatures of short motifs from a query
fragment to a reference genome – for instance, a particular
GC content, gene and protein family content, or k-mer
frequency and distribution [71]. Composition based
approaches include Phylopythia [118], PhylopythiaS
[119], Phymm [120], the Naive Bayes Classifier [121],
Sequedex [122], the Livermore Metagenomic Analysis
Toolkit (LMAT) [97], GENIUS [96] and Kraken [99].
Alignment-based approaches compare reads to a set
of labeled reference genomes using a basic local alignment
search tool (BLAST)-based approach. Alignment based
approaches include MEGAN, Bowtie, MetaPhlAn,
MetaPhyler, CARMA, WebCARMA, IMG/M, MG-RAST,
and others [98,116,123-132]. Additionally, methods for dir-
ect taxonomic classification of sequencing reads use a
combination of both composition and sequence simi-
larity approaches, such as MetaCluster [133], Rapid
Identification of Taxonomic Assignments [134], and
PhymmBL [127,128,135]. A more comprehensive review
of sequence classification methodology and software is
presented elsewhere [136].
Many programs use a phylogenetic approach to classify
sequences and summarize results by taxonomic group. A
sequence(s) can be assigned at any level from the phylum
down to the species and strain. The output of the program
may potentially assign a sequence(s) to any taxonomic
level. Most commonly, a program will summarize the
overall abundance of each taxonomic level it detects. If a
species is detected and no other higher resolving sequence
data are available, then strains within that species cannot
be resolved based on that sequence data. Many pro-
grams may achieve assignment to the genus level, but not
to species level attribution. Some programs conduct
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programs will assign to a variety of levels depending on
the level of specificity of the input data. Programs
designed to make assignment at the strain level for
bacteria will need to be validated for that level of
specificity as well as congruency with genus and species
level summaries. Viral strain assignment poses additional
challenges, as some viruses (for example, RNA viruses)
can have high rates of mutation and form quasi-species
for which no clear reference genomes are available [107].
Bacterial and virus level assignments are likely to improve
as the number of sequenced microbial genomes continues
to increase. Since phylogenetic assignments are based
on extant data, the databases and software (and version)
used to perform the phylogenetic analyses should be
documented.
Software typically is run with thresholds for assignment
likelihood that can be set at either the initiation of analysis
or at the time of interpretation of output. The thresholds
used for analysis should be defined and documented
thoroughly. Documentation should include the step(s) at
which thresholds are specified, either by user input, within
configuration files, in output interpretation, or at any
other step in the analytical process. Thresholds should not
be assumed to be equivalent between programs or within
different versions of the same program, as every step
of the analysis can impact the odds or strength of
assignment. While many thresholds for taxonomic assign-
ment are set automatically, the user has a responsibility to
design experiments that test the impact of thresholds on
the output of known samples on taxonomic assignment
and set those thresholds accordingly.
Abundance levels
The most basic measure of the abundance of an organism
in a sample is binary abundance (that is, presence/absence).
Proportional abundance provides information on a
continuous scale, but usually does not accurately convey
relative level of abundance. The current state-of-the-art is
generally composed of abundance measures with no
associated confidence values [97,122,127]. Because of the
complex nature of metagenomic samples a stochastic
threshold (or minimum abundance threshold) for
detection should be implemented. The abundance
threshold can be set empirically to where anything above
that value is present and anything lower (below the limit
of detection) is either inconclusive, not detected, or
absent, but then should be used consistently to measure
corresponding error rates. The degree of accuracy is tied
to the threshold of detection that is set. Internal standards
are useful. Most studies to date have collected metage-
nomic data in a relative framework, in which abundance
of genes or messages is calculated as percent or propor-
tion of the sample content. However, the abundance levelcan be more accurate if internal genomic DNA is added at
the sample processing stage. If these control molecules are
mixed into and processed alongside the sample-derived
nucleic acids, more effective quantification and inter-
sample comparisons may be performed. Internal
controls also may provide information on the extent
or directionality of changes in any particular gene or
organisms present. For example, in tracking a particular
source of a contamination, measuring a gradient pointing
towards the source may be useful. When drawing a
conclusion that the presence of a microorganism is, for
example, inconclusive or absent, it should be stated as
being below the limit of detection that is determined both
by the amount of sequence data and the parameters at
which the analysis program was benchmarked.
Organism classification
Taxonomic classification of bacteria can sometimes create
the misconception that microbial species are discrete and
unique entities. Rather, some species are extremely closely
related to each other and may form a continuum that is
not readily resolved, while others are extremely distant
from other microorganisms and can be categorized
effectively [106]. Unfortunately, some separately named
strains have almost identical genomes, while others are
more dissimilar than some pairs of species. Therefore,
when evaluating the power with which genomics can be
used to distinguish between and among microorganisms
and, thereby, define attribution under the circumstance of
the analysis (for species to strain level identification or for
determining similarity between two or more samples), it is
important to understand the level of genomic similarity
that they share (with known diversity of extant isolates).
Also, the diversity in sequence within a species should be
appreciated.
When constructing a test dataset for benchmarking, a
decision first must be made regarding the level of
genomic discrimination required. The level of genomic
discrimination will likely be based on a list of known
microorganisms of interest compared to their near
neighbors. Whether that value is 5%, 1%, 0.1% or less,
the microorganisms used for thresholding must have
degrees of similarity consistent with that threshold. When
calculating the similarity of two genomes, there are at
least two methods that could be used: 1) calculating
the similarity of regions and genes that are shared, or
2) normalizing that alignment value to the proportion of
each genome that can be aligned. The second approach
may account for plasmids or horizontally-transferred
elements that may distinguish two strains of the same
species. However, those strain-specific genes or regions
may not provide any added discriminatory power to an
algorithm depending on how it is constructed. One
approach may be the percent identity of common (shared)
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genomes, so that the relationship of strains with a
high degree of similarity within the core genome is
not confounded by the presence of mobile elements.
The performance of an algorithm should be presented
only in the context of the degree of similarity between the
organisms used for validation, with probability estimate, if
possible.
Another strategy for selecting microorganisms for
benchmarking is to use specific microorganisms that
are of particular interest. For example, discriminating
between a threat agent (such as B. anthracis) and a
close relative (such as B. cereus) may be a higher priority
than discriminating between all known species that are
differentiated by at least 1%. It is important to note that
such a specific target approach cannot be applied to
benchmarking studies of other microorganisms as they
may not, and likely will not, have a comparable level of
genomic dissimilarity. The documented goal(s) of the user
will determine whether the validation is designed to assess
global similarity measures or the similarity of specific
target organisms to their near neighbors.
Community structure
In addition to containing many different microorganisms,
whether the same ones or very different ones, metagenomic
samples will differ dramatically according to the relative
abundances of microorganisms comprising the sample.
Abundances of each microorganism (or taxonomic level of
resolution) will vary widely, so that performance will be
judged across orders of magnitude. It is difficult to predict
how the presence of one microorganism may modu-
late the detection of another (due to similar elements
in those genomes and power of discrimination of the
bioinformatic method). The relative abundances of each
organism can be varied across a number of replicates if
the method lacks discriminatory power. This evaluation is
performed best in silico.
The output data from a series of validation tests should
consist of a set of records containing:
1. Microorganism (or taxonomic level resolved).
2. Known abundance, for example, controls.
3. Measured abundance (either proportional or binary).
4. If possible, a confidence measure
(or qualitative/quantitative statement).
Sets of independent tests and repetitive tests will allow
for summary statistics to be applied for assessing attribu-
tion capabilities, as well as the performance of the analytical
system as a whole. Since empirical data generation is
demanding and costly, the use of simulation data is strongly
recommended. Power testing also can be defined, based on
the number of samples to be analyzed. Comparisons ofabundance values of microbes in two or more samples may
be used for potentially indicating association [137]. Relevant
to such analyses may be population genetic quantities, such
as alpha and beta diversities [138]. The appropriate criteria
for abundance distributions and comparisons should be
established during validation. Current software may per-
form such data analyses to a degree and it is anticipated
that novel programs will become available.
Rates of FPs and FNs are important measures and
correspond to the sensitivity and specificity of the assay. If
a proportional abundance measure is given, an abundance
threshold should be set to render an interpretation of
presence/inconclusive/absence. If a confidence measure is
given, a more stringent threshold can be used along that
dimension as well. Threshold values are dependent on the
parameters of the sequencing run, as well as the program
used and reference database. A validation process that
establishes confidence values for a particular set of output
data will only be applicable to other samples that are
processed on the same platform, using the same settings
(read length, and so on), filtered and processed with the
same Q-score cutoffs, and then analyzed with the same
taxonomic assignment program run with identical
settings. This process is extremely important because the
results of the validation process cannot be extended
directly to an analysis in which any of those parameters
have been changed or do not match.
The accuracy of proportional abundance can be
measured with a correlation coefficient, either parametric
(for example, Pearson) or nonparametric (for example,
Spearman). Pearson’s test could indicate how closely the
absolute values generated resemble the known composition,
while Spearman’s test could indicate how closely the
generated rank-order of each organism resembles the
known composition. The utility of a program in determin-
ing the proportional abundance of individual microor-
ganisms within a sample depends on the value of the
correlation coefficient with data for controls included
in the analysis. However, for many forensic applications the
relative abundance of an organism is far less important than
the presence or absence of that organism, along with desig-
nation to the strain level of identification. Nevertheless, for
applications in which relative abundance is to be reported
with confidence, thorough validation must satisfy all
requirements of a binary presence analysis, with the
added dimension of the correlation coefficient.
Standard operating protocols or procedures
All validated assays require SOPs, which must be based
on the results of validation that encompass all appropriate
aspects of the assay process, including but not limited to:
sample collection and storage, nucleic acid extraction,
enrichment, library preparation, sequencing, data analysis
and interpretation of results. SOPs for implementation of
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optimization; (3) validation; and (4) automation [139].
These concepts, while initially developed for HTS-based
microbial clinical diagnostics, apply equally to developing
HTS SOPs for microbial forensics. Standardization, in this
context, requires selecting a set of methods, software and
workflows, along with setting thresholds for making a
forensic interpretation based on features present in the
HTS data set. SOPs themselves must be validated, ideally
with blinded prospective studies using static data analysis
workflows. Finally, data analysis and interpretation SOPs
ideally should be fully automated, if possible, to reduce
user-configurable parameters to a minimum [139].
Conclusions
Conveying confidence in a test or process is essential in
microbial forensics because the consequences are serious
and the conclusions must be based on data and resultant
interpretations of evidence in the case of a biothreat
event. Therefore, the limitations of methods used in
microbial forensics to generate results must be reliable
and defensible and the process(es) of validation will
contribute substantially in defining confidence associated
with an assay, method, or system. HTS is an invaluable
tool, expanding the scope and power of microbial
forensics to provide protection against and response to
attacks with biological agents. The HTS process was
described in some detail herein so that analysts, who are
not experienced researchers, will have guidance on the
features and criteria that should be addressed during a
validation. An outline of the HTS validation criteria is
provided in the list of elements below. The reader may
consider such validation quite challenging. However, similar
demands have been in place for forensic human identifica-
tion and the benefits to that forensic science community
outweigh the task of validation. It is difficult to lay out the
highest priority or near-term goals here as these may vary
with the test or application and, therefore, such decisions
are left to the community of users. To accomplish a
validation the investigator should develop criteria as
he or she requires for each situation. However, the
criteria and the results and conclusions from validation
studies must be available for inspection by appropriate
parties.
List of elements to consider during validation of HTS for
microbial forensicsa
I. Sample Preparation
a. Template (DNA or RNA) quantity and quality
i. Minimum and maximum requirements
ii. Guidelines for action when these values fall
out of range
b. Enrichmenti. Desired genomic regions for enrichment
ii. Limitations of the chosen method (for example,
introduces known bias, increases error) and
specific circumstances for its justified use
c. Library preparation
i. Quality, sensitivity, reproducibility and
robustness of library preparation method(s)
across expected sample types
d. Multiplexing













5. Potential for carry over contaminationIII. Data analysis






5. Allele call (SNP state, indel state, and so on)
6. Threshold
7. False positive and false negative rates
iii. Reference standard
1. Variant calling
2. Gene or functional element assignment
iv. Alignment- or composition-based software
1. Functions
2. Rules for alignment
v. Phylogenetics software
1. Functions
b. Bioinformatics software management
IV. Controls







ii. Complex or metagenomic
1. Abundance
iii. FP and FN rates




iii. Reverse engineering1. Sample preparation
2. Genetic engineering














iv. InterpretationaIt is not possible to generate an all-inclusive element
list because of the wide diversity of samples, sample
types, chemistries, platforms, and bioinformatics for
which HTS methods may be applied. Therefore, this
outline serves as a guideline, rather than an exhaustive
or prescriptive regulation. The user should evaluate
these elements, select those that apply, justify why some
elements were not applied, and add any elements that
are method specific and not included in this outline.
The HTS validation process should, at a minimum: 1)
ensure that appropriate reference and benchmarking
datasets are used to establish FP and FN values within a
rigorous statistical framework; and 2) require the practices,
chemistries, settings, and bioinformatics programs used to
generate actionable results be thoroughly documented and
standardized, at least within the specific laboratory employ-
ing the method(s). It is important to remember that identi-
fication to species and strain is highly dependent on
phylogenetic similarity of near neighbors used for compari-
son. Consequently, the validation of a process to detect a
given species or strain cannot be applied indiscrimin-
ately to additional target organisms without additional
validation. The ability of a process to identify to spe-
cies level varies across the tree of life, and validation
processes must take the phylogenetic framework into
consideration.
The validation process described herein allows for trans-
lation of research tools to forensic applications so that HTS
can provide the reproducibility and specificity necessary to
stand up to the full weight of legal scrutiny. In addition to
validation, the laboratory is urged to adopt an overallquality management and quality assurance system to pro-
vide a working foundation essential for microbial fo-
rensics, maintaining good laboratory practices and
bolstering confidence in results.
As HTS technologies continue to advance, costs will
continue to drop, instruments will become faster, smaller,
eventually portable, and their applications continue to
increase. Advanced sequencing technologies will begin to
be applied to measuring DNA modifications, epigenetic fac-
tors and offer yet another layer of specificity. With longer
reads, genetically engineered organisms will be detected,
most likely by identification of unexpected adjacency of
genomic elements. The validation criteria described in this
paper may likely apply to the new analytical flourishes in
the coming years and, therefore, provide a stable foundation
for future implementation in microbial forensics. If methods
are validated within the framework outlined here, microbial
forensics will achieve an ever higher level of power and
analytical value and, ultimately, greater protection for the
public and the nation’s safety and security.
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